HI
ABUS icon

Harbour Investments’s Arbutus Biopharma ABUS Stock Holding History

Harbour Investments’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-700
Closed -$3K – 2610
2021
Q3 		$3K Buy
700
+500
+250% +$1.67K ﹤0.01% 3143
2021
Q2 		$1K Hold
200
– – ﹤0.01% 3481
2021
Q1 		$1K Buy
+200
New +$772 ﹤0.01% 3315

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

Harbour Investments's ABUS Position: Q4 2021 in Review

Harbour Investments sold out of Arbutus Biopharma (ABUS) in Q4 2021, closing a stake of 700 shares — an estimated $3K sold.

Harbour Investments first reported a position in ABUS in Q1 2021 and held it in 3 quarters. The position peaked at $3K in Q3 2021. 122 funds tracked by Wall St. Rank hold ABUS as of Q4 2021.

  • Harbour Investments reported no remaining Arbutus Biopharma position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 700 Arbutus Biopharma shares in Q4 2021, an estimated $3K.
  • Harbour Investments first reported a position in Arbutus Biopharma in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's Arbutus Biopharma position peaked at $3K in Q3 2021.
  • 122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.